Led by core company KYORIN Pharmaceutical Co., Ltd., the Kyorin Group is focusing sales activities in respiratory medicine, otolaryngology, and urology on advancement of its franchise customer strategy, as well as strengthening relationships with physicians and other medical professionals to enhance our domestic marketing platform.

Key products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn’s disease; and Uritos, for treating overactive bladder.

In research and development, the Kyorin Group has established a trilateral drug discovery network encompassing KYORIN Pharmaceutical Co., Ltd. (Japan), ActivX Biosciences, Inc. (United States), and Kyorin-Scotland Research Laboratories (Europe), promoting the efficient development of attractive new products.

• Learn more: Ethical Drugs

This business is led primarily by KYORIN Rimedio Co., Ltd., which focuses on the manufacture and sale of generic drugs

We see considerable growth potential for generic drugs in Japan's ethical drug market, and their importance is growing as Japan’s Ministry of Health, Labour and Welfare continues to promote the use of generic drugs as a means of curbing domestic healthcare costs. To capitalize on this opportunity, we are 1) strengthening sales capabilities by increasing the number of medical representatives and securing buyers; 2) lowering cost of sales ratios by increasing production rates; and 3) working to expand our product lineup by promoting more efficient, effective research and development.

• Learn more: Generic Drugs

In the consumer healthcare business, we are putting all our effort into expanding sales of Milton, a baby bottle disinfectant highly regarded by obstetricians and midwives. We are also working to strengthen sales of our core products - Switch OTC drugs. These are nonprescription drugs which incorporate proven ingredients from existing ethical drugs.

Other businesses include KYORIN Medical Supply Co., Ltd. which is responsible for planning and production of promotional materials and advertising, and sales of medical promotional tools and packaging materials to third parties including KYORIN Pharmaceutical and KYORIN Remedio.

Within the Kyorin Group, KYORIN Medical Supply is also responsible for working to enhance shared services, and for the creation of new businesses within the healthcare field.

• Learn more: Over the Counter Drugs and Others

Dr. Program Co., Ltd., which develops and sells cosmetics using drug formulation technology, is rolling out skincare products targeting women over 40. The Kyorin Group is also working to enhance its lineup of high value-added products and to expand its base of repeat customers, rather than simply increase customer numbers, while also focusing on strengthening its operating base through collaboration between Group companies.

• Learn more: Consumer Healthcare

The Kyorin Group’s research and development activities are pursued through a trilateral drug discovery network encompassing KYORIN Pharmaceutical Co., Ltd. in Japan, ActivX Biosciences, Inc. in the United States, and Kyorin-Scotland Research Laboratories in Europe. Taking advantage of the close ties between divisions, which work to verify the synthesis, pharmacology, ADME (Absorption, Distribution, Metabolism, Excretion), and safety of new drugs, we work to promote the efficient development of attractive new products.

• Learn more: Research and Development

Please refer to Products Under Development

• Learn more: Products Under Development

Through proactive collaboration with outside firms, the Kyorin Group is working to enrich our R&D pipeline and to maximize the value of our original products.

• Learn more: Alliance Strategies